Skip to content

Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation

Satisfaction of Patients With Amyotrophic Lateral Sclerosis Under Non-invasive Ventilation Regarding Home Assisted Teleconsultation

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05621213
Acronym
VNI_SLA
Enrollment
38
Registered
2022-11-17
Start date
2023-01-13
Completion date
2025-09-05
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS, Charcot Disease

Brief summary

Satisfaction of patients with amyotrophic lateral sclerosis under non-invasive ventilation regarding home assisted teleconsultation

Detailed description

Amyotrophic Lateral Sclerosis (ALS) is a progressive and rapidly progressing neurodegenerative disease. Depending on the degree of muscle damage, patients may suffer from reduced mobility, difficulty swallowing, speech difficulties and finally respiratory weakness. Death occurs within an average of 2-3 years and is usually due to respiratory failure. Currently there is no cure for ALS, so palliative care and symptomatic treatments are essential for the management of these patients. The gold standard treatment for respiratory impairment is non-invasive ventilation (NIV). The aim of this mask ventilation is to improve gas exchange by compensating for the weakness of the respiratory muscles. The progressive nature of ALS requires regular assessment of the patient's clinical condition and evaluation of NIV parameters. Regular medical appointments are therefore essential to ensure optimal ventilation and close surveillance of the patient. A day hospitalization or a consultation is organized every 3 or 4 months. These visits can cause significant fatigue, not only because of the difficulty patients have to move around but also because of the time spent waiting in hospital. ALS is characterised by its severity and it requires our society to think about and implement new ways of managing the disease. Thus, e-health innovations could be an interesting potential in the remote follow-up of these patients, to reduce the burden of hospital consultations. The hypothesis is that the patient will be more satisfied with a home assisted teleconsultation follow-up, while keeping the same quality of non-invasive nocturnal ventilatory assistance.

Interventions

OTHERTeleconsultation assisted by a physiotherapist or nurse

A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions. This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.

Sponsors

AGIR à Dom
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Patient assigned to the interventional group or to the control group if they do not wish to be followed up by teleconsultation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with a diagnosis of ALS coming for a follow-up consultation with their pneumologist * Daily NIV compliance of more than 4 hours in the month prior to inclusion * Living at home * Patient with a natural caregiver * Patient equipped with computer equipment adapted for teleconsultation (tablet, computer, telephone... with an internet connection) * Patient able to read and understand the procedure, and able to express consent for the study protocol * Patient, or his or her caregiver, able to sign the consent to participate by himself or herself

Exclusion criteria

* Patient not available or wishing to change region within 3 months of inclusion * Patient currently participating or having participated in the month prior to inclusion in another clinical interventional research study that may have an impact on the study, this impact is left to the discretion of the investigator * Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons) * Pregnant women (for women of childbearing age and in the absence of reliable contraception, the β-HCG (human chorionic gonadotropin) assay will be performed), parturient women, breastfeeding women, * persons deprived of their liberty by judicial or administrative decision, * persons under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Satisfaction of ALS patients followed by teleconsultation at homeBetween the initial visit and the 3-month visitEvolution of the overall satisfaction score obtained from the Client Satisfaction Questionnaire CSQ-8, with 8 items, score 8-32. The higher the score, the more satisfied the patient is.

Secondary

MeasureTime frameDescription
Evolution of the patient's physical functionsBetween the initial visit, the 3-month visit, and the 6-months visitChange in ALS-FRS-R (Amyotrophic lateral sclerosis functional rating scale revised) questionnaire score, score 0-48. The higher the score, the better the patient's physical function.
Non-inferiority of ventilatory efficiency compared to conventional managementBetween the initial visit, the 3-month visit, and the 6-months visitNon-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visitBetween the initial visit, the 3-month visit, and the 6-months visitComparison of the evolution of ventilation efficiency assessed from clinical parameters measured by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire, score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Patient satisfaction with teleconsultation itself (use and patient/doctor interaction)After each teleconsultation (3-month visit and 6-month visit)Evaluation of the score of the Visit Satisfaction Questionnaire (VSQ-VF) score 0-100. The higher the score, the more satisfied the patient is.
The evolution of satisfaction between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visitBetween the 3-month visit, and the 6-months visitComparison of the variation in the score of the visit satisfaction questionnaire, assessed by the VSQ-VF questionnaire, score 0-100. The higher the score, the more satisfied the patient is.
Physician satisfaction with teleconsultationAfter each teleconsultation (3-month visit and 6-month visit)Evaluation made by Visual Analogue Scale (VAS) from 0 to 10 cm. The higher the score, the more satisfied the physician is.
Caregivers' satisfaction with the care of the relativeBetween the initial visit, the 3-month visit, and the 6-months visitChange in caregiver satisfaction measured with client satisfaction questionnaire score (CSQ-8 modified) with 8 items, score 8-32. The higher the score, the more satisfied the caregivers' is.
The feasibility of home teleconsultation for ALS patientsBetween the initial visit, the 3-month visit, and the 6-months visitNumber of failed teleconsultations requiring rescheduling
Retention of follow-up modalityAt 6 monthsNumber of patients who changed follow-up modality, assessed by the number of face-to-face follow-up

Countries

France

Contacts

PRINCIPAL_INVESTIGATORChristel Saint-Raymond, PhD

CHU Grenoble Alpes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026